Employees Provident Fund Board Takes $25.69 Million Position in Amgen Inc. $AMGN

Employees Provident Fund Board acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 78,500 shares of the medical research company’s stock, valued at approximately $25,694,000.

Several other institutional investors and hedge funds have also modified their holdings of AMGN. Anfield Capital Management LLC raised its position in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares during the last quarter. Dogwood Wealth Management LLC lifted its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund acquired a new position in Amgen in the 4th quarter worth $26,000. Manning & Napier Advisors LLC raised its position in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC acquired a new position in Amgen during the fourth quarter worth $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.85% of the stock is currently owned by insiders.

Amgen Stock Performance

AMGN opened at $337.60 on Friday. The company has a fifty day moving average price of $340.71 and a two-hundred day moving average price of $345.76. The company has a market cap of $182.21 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the company posted $4.90 earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts predict that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on AMGN shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 target price on shares of Amgen in a research note on Wednesday, April 8th. Wells Fargo & Company lifted their price objective on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. Jefferies Financial Group began coverage on shares of Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective for the company. Barclays assumed coverage on Amgen in a research note on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective on the stock. Finally, Leerink Partners restated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Amgen has a consensus rating of “Hold” and a consensus price target of $354.42.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.